Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TRIL - Trillium Therapeutics Inc

Previous close
18.44
0   0%

Share volume: 0
Last Updated: Tue 16 Nov 2021 06:00:00 AM CET
Biological Product (except Diagnostic) Manufacturing : -3.41%

PREVIOUS CLOSE
CHG
CHG%
$18.44
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 45%
Dept financing 25%
Liquidity 49%
Performance 42%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$18.44
P/E Ratio 
0.00
DAY RANGE
$18.44 - $18.44
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
104.995 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO:
Region: US
Website: www.trilliumtherapeutics.com
Employees: 33
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biological Product (except Diagnostic) Manufacturing
Sector: Manufacturing

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

Recent news